Management of patients with decompensated HBV cirrhosis

被引：60
作者：
Fontana, RJ [1 ]
机构：
[1] Taubman Ctr 3912, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Div Gastroenterol, Ann Arbor, MI USA
来源：
SEMINARS IN LIVER DISEASE | 2003年 / 23卷 / 01期
关键词：
liver transplantation; lamivudine; hepatitis B; adefovir;
D O I：
10.1055/s-2003-37591
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Patients with decompensated hepatitis B virus (HBV) cirrhosis have a poor prognosis due to the development of progressive liver failure and hepatocellular carcinoma. Lamivudine appears to be a safe and effective antiviral agent, which may improve or stabilize liver disease in selected patients with advanced cirrhosis and active HBV replication. However, viral resistance can develop with prolonged treatment and some patients with advanced cirrhosis may not experience any discernible benefit. The use of hepatitis B immunoglobulin prophylaxis with or without lamivudine has resulted in excellent survival and a low rate of graft reinfection in patients who undergo liver transplantation for decompensated HBV cirrhosis. Adefovir and entecavir are newer antiviral agents that have activity against both wild-type and lamivudine-resistant HBV. Additional studies of individual or combination antiviral agents are urgently needed to improve further the prospects for the large number of patients worldwide with decompensated HBV cirrhosis.
引用
收藏
页码：89 / 100
页数：12
相关论文
共 90 条
[1]  
Ahmed A, 1999, AM J GASTROENTEROL, V94, P249, DOI 10.1111/j.1572-0241.1999.00808.x
[2]   Identification and characterization of mutations in hepatitis B virus resistant to lamivudine [J].
Allen, MI ;
Deslauriers, M ;
Andrews, CW ;
Tipples, GA ;
Walters, KA ;
Tyrrell, DLJ ;
Brown, N ;
Condreay, LD .
HEPATOLOGY, 1998, 27 (06) :1670-1677
[3]   Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B [J].
Angus, PW ;
McCaughan, GW ;
Gane, EJ ;
Crawford, DHG ;
Harley, H .
LIVER TRANSPLANTATION, 2000, 6 (04) :429-433
[4]   Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation [J].
Aye, TT ;
Bartholomeusz, A ;
Shaw, T ;
Bowden, S ;
Breschkin, A ;
McMillan, J ;
Angus, P ;
Locarnini, S .
JOURNAL OF HEPATOLOGY, 1997, 26 (05) :1148-1153
[5]  
BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO
[6]  
2-J
[7]  
BENVEGNU L, 1994, CANCER, V74, P2242
[8]  
Berenguer M, 2001, AM J GASTROENTEROL, V96, P526, DOI 10.1111/j.1572-0241.2001.03554.x
[9]   Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B [J].
Chien, RN ;
Liaw, YF ;
Atkins, M .
HEPATOLOGY, 1999, 30 (03) :770-774
[10]   Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection [J].
de Man, RA ;
Wolters, LMM ;
Nevens, F ;
Chua, D ;
Sherman, M ;
Lai, CL ;
Gadano, A ;
Lee, Y ;
Mazzotta, F ;
Thomas, N ;
DeHertogh, D .
HEPATOLOGY, 2001, 34 (03) :578-582
123456789